Uden D L, Seay R E, Kriesmer P J, Cipolle R J, Payne N R
University of Minnesota College of Pharmacy, Minneapolis.
ASAIO Trans. 1991 Apr-Jun;37(2):88-91.
Whole blood activated clotting time (ACT) can be determined by many different methods that use a variety of clotting cascade activators and end-points. This study compared the results of three whole blood ACT instruments at equivalent concentrations of heparin. Whole blood (9.8 ml) from 10 healthy adult volunteers without coagulation abnormalities was added to 0.2 ml of heparin solution producing heparin concentrations of 0, 0.1, 0.2, 0.4, 0.6, 0.8, and 1.0 U/ml. Coagulation status was determined in duplicate with the Hemochron 400 System (HC), the HemoTec Automated Coagulation Timer (HT), and the TriMed ACTivator (TM). Thrombin times or dilutions (TT) were also determined for each sample. Baseline values did not differ (p greater than 0.05); however, the HT and TM ACT values were significantly longer (p less than 0.05) than the HC ACT values at predicted heparin concentrations greater than 0.2 U/ml. Results from the HT and TM instruments were not significantly different. The HT and TM instruments both provided a greater ACT range over the heparin concentrations tested. Of the tests studied to monitor heparin therapy, mean scaled TTs showed the best correlation with predicted heparin concentrations.
全血活化凝血时间（ACT）可通过多种不同方法测定，这些方法使用各种凝血级联激活剂和终点指标。本研究比较了三种全血ACT仪器在等效肝素浓度下的结果。将来自10名无凝血异常的健康成年志愿者的全血（9.8 ml）加入0.2 ml肝素溶液中，使肝素浓度分别为0、0.1、0.2、0.4、0.6、0.8和1.0 U/ml。使用Hemochron 400系统（HC）、HemoTec自动凝血计时器（HT）和TriMed ACTivator（TM）对凝血状态进行重复测定。还对每个样本测定了凝血酶时间或稀释度（TT）。基线值无差异（p大于0.05）；然而，在预测肝素浓度大于0.2 U/ml时，HT和TM的ACT值显著长于HC的ACT值（p小于0.05）。HT和TM仪器的结果无显著差异。在测试的肝素浓度范围内，HT和TM仪器均提供了更大的ACT范围。在所研究的用于监测肝素治疗的测试中，平均标化TT与预测肝素浓度的相关性最佳。
